Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers

Toxicology Letters

Volumn 190, Issue 1, 2009, Pages 54-60

  Meyer, Markus R ^a   Peters, Frank T ^a,b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cytochrome P450; Designer drugs; Enantiomers; Metabolism

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL) N METHYL 2 BUTANAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 4 METHYLCATECHOL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME;

ARTICLE; CONCENTRATION PROCESS; CONTROLLED STUDY; DEMETHYLATION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME METABOLISM; HETEROLOGOUS EXPRESSION; HUMAN; PRIORITY JOURNAL;

3,4-METHYLENEDIOXYAMPHETAMINE; ANTIBODIES, MONOCLONAL; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KINETICS; MICROSOMES, LIVER; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STEREOISOMERISM; STREET DRUGS;

EID: 68349154511     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.06.866     Document Type: Article

References (42)

1. Bourrie M., Meunier V., Berger Y., and Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277 (1996) 321-332
2. Brunnenberg M., and Kovar K.A. Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans. J. Chromatogr. B: Biomed. Sci. Appl. 751 (2001) 9-18
3. Buechler J., Schwab M., Mikus G., Fischer B., Hermle L., Marx C., Gron G., Spitzer M., and Kovar K.A. Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 793 (2003) 207-222
4. Clarke S.E. In vitro assessment of human cytochrome P450. Xenobiotica 28 (1998) 1167-1202
5. Crespi C.L., and Miller V.P. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol. Ther. 84 (1999) 121-131
6. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., and Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26 (2004) 137-144 (review)
7. Easton N., and Marsden C.A. Ecstasy: are animal data consistent between species and can they translate to humans?. J. Psychopharmacol. 20 (2006) 194-210 (review)
8. Erives G.V., Lau S.S., and Monks T.J. Accumulation of neurotoxic thioether metabolites of 3,4-(±)-methylenedioxymethamphetamine in rat brain. J. Pharmacol. Exp. Ther. 324 (2008) 284-291
9. Evenson M.A., and Lensmeyer G.L. Qualitative and quantitative determination of methaqualone in serum by gas chromatography. Clin. Chem. 20 (1974) 249-254
10. Fallon J.K., Kicman A.T., Henry J.A., Milligan P.J., Cowan D.A., and Hutt A.J. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin. Chem. 45 (1999) 1058-1069
11. Freudenmann R.W., and Spitzer M. The neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev. 10 (2004) 89-116
12. Grime K., and Riley R.J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 7 (2006) 251-264
13. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz-de-Montellano P.R. (Ed). Cytochrome P450-Structure, Mechanism, and Biochemistry. 3rd ed. (2005), Kluwer Academic/Plenum Publishers, New York 377-530
14. Hegadoren K.M., Baker G.B., and Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci. Biobehav. Rev. 23 (1999) 539-553 (review)
15. Johnson M., Letter A.A., Merchant K., Hanson G.R., and Gibb J.W. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J. Pharmacol. Exp. Ther. 244 (1988) 977-982
16. Johnson M.P., and Nichols D.E. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacol. Biochem. Behav. 33 (1989) 105-108
17. Jones D.C., Lau S.S., and Monks T.J. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J. Pharmacol. Exp. Ther 311. (2004) 298-306
18. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can. Med. Assoc. J. 165 (2001) 917-928 (review)
19. Ko J.W., Sukhova N., Thacker D., Chen P., and Flockhart D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 25 (1997) 853-862
20. Kraemer T., and Maurer H.H. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives. Ther. Drug Monit. 24 (2002) 277-289 (review)
21. Kreth K., Kovar K., Schwab M., and Zanger U.M. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol. 59 (2000) 1563-1571
22. Lin L.Y., Di Stefano E.W., Schmitz D.A., Hsu L., Ellis S.W., Lennard M.S., Tucker G.T., and Cho A.K. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25 (1997) 1059-1064
23. Maurer H.H. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 18 (1996) 465-470
24. Maurer H.H., Bickeboeller-Friedrich J., Kraemer T., and Peters F.T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol. Lett. 112 (2000) 133-142
25. Meyer M.R., Peters F.T., and Maurer H.H. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic MDMA and its enantiomers. Drug Metab. Dispos. 36 (2008) 2345-2354
26. Meyer M.R., Peters F.T., and Maurer H.H. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem. Pharmacol. 77 (2009) 1725-1734
27. Meyer M.R., Peters F.T., and Maurer H.H. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic MDEA and its single enantiomers. Drug Metab. Dispos. 37 (2009) 1152-1156
28. Monks T.J., Jones D.C., Bai F., and Lau S.S. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther. Drug Monit. 26 (2004) 132-136 (review)
29. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23 (1995) 154-158
30. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs 18 (1986) 305-313
31. Nichols D.E., Hoffman A.J., Oberlender R.A., Jacob P., and Shulgin A.T. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J. Med. Chem. 29 (1986) 2009-2015
32. Perfetti X., O'Mathuna B., Pizarro N., Cuyas E., Khymenets O., Almeida B., Pellegrini M., Pichini S., Monks T.S., Lau S.S., Farre M., Pascual J.A., Joglar J., and de la Torre R. Neurotoxic thioether adducts of MDMA identified in human urine after ecstasy ingestion. Drug Metab. Dispos. (2009)
33. Peters F.T., Kraemer T., and Maurer H.H. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin. Chem. 48 (2002) 1472-1485
34. Peters F.T., Samyn N., Lamers C., Riedel W., Kraemer T., de Boeck G., and Maurer H.H. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective determination of the designer drugs MDA, MDMA (Ecstasy) and MDEA and its application to samples from a controlled study with MDMA. Clin. Chem. 51 (2005) 1811-1822
35. Peters F.T., Samyn N., Wahl M., Kraemer T., de Boeck G., and Maurer H.H. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J. Anal. Toxicol. 27 (2003) 552-559
36. Pizarro N., Farre M., Pujadas M., Peiro A.M., Roset P.N., Joglar J., and de la Torre R. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab. Dispos. 32 (2004) 1001-1007
37. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997) 413-580
38. Sauer C., Peters F.T., Schwaninger A.E., Meyer M.R., and Maurer H.H. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) and N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA). Chem. Res. Toxicol. 21 (2008) 1949-1955
39. Schifano F., Corkery J., Deluca P., Oyefeso A., and Ghodse A.H. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J. Psychopharmacol. 20 (2006) 456-463
40. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., and Chu T.Y. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47 (1994) 1151-1156
41. Venkatakrishnan K., von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., and Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28 (2000) 1493-1504
42. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 41 (2001) 1149-1179